PBI 01011
Alternative Names: PBI-01011Latest Information Update: 08 Sep 2022
At a glance
- Originator Phoenix Biotechnology
- Class Neuroprotectants; Oleanolic acids; Triterpenes
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Clinical Phase Unknown Neurodegenerative disorders
Most Recent Events
- 01 Sep 2022 Clinical trials in Neurodegenerative disorders in USA (unspecified route) (Phoenix Biotechnology pipeline, September 2022)
- 04 Jun 2019 Phoenix Biotechnology has granted patent for extract of Nerium species for neurological disorders in USA
- 17 Apr 2019 Phoenix Biotechnology has patents pending for extract of Nerium species for neurological disorders in USA